智通财经网·2025-12-22 12:02Core Viewpoint - The company, Baiyunshan (00874), has approved investments through its subsidiary, Guangyao Phase II Fund, into two new funds aimed at enhancing its presence in the biopharmaceutical sector, particularly in innovative drugs, modern traditional Chinese medicine, and high-end medical devices [1] Group 1 - The board approved a partnership agreement for Guangyao Phase II Fund with Guangyao Capital and Guangkai Fund, with respective contributions of RMB 97.5 million, RMB 2.5 million, and RMB 100 million to establish the Guangyao Guangkai Fund [1] - A second partnership agreement was approved for Guangyao Phase II Fund with Guangyao Capital, Angel Mother Fund, and Liwan Industrial Investment Fund, with contributions of RMB 99.5 million, RMB 3.5 million, RMB 98.5 million, and RMB 98.5 million to establish the Guangyao Liwan Fund [1] - These investments align with the investment direction of Guangyao Phase II Fund, aiming to expand its investment scale, diversify risks, and accelerate investment pace and efficiency [1] Group 2 - The strategy involves early, small, and future-oriented investments to engage with quality enterprises at the source, fostering and incubating potential companies [1] - The approach is designed to facilitate technological upgrades and value chain extensions, transitioning the company from a traditional business model to one driven by technological innovation [1] - This transition is expected to lay a solid foundation for high-quality development [1]